糖尿病是一種慢性代謝疾病，主要表現(xiàn)為高血糖和微血管并發(fā)癥。糖尿病患者中有90%～95%為2型糖尿病。近年來2型糖尿病的藥物研究重心逐漸從傳統(tǒng)致病機制的研究轉(zhuǎn)移到新作用靶點、新致病機制的研究。以國內(nèi)外相關(guān)文獻(xiàn)為基礎(chǔ)，按照作用機制介紹了一些在臨床使用的2型糖尿病治療藥物或正在研制的有關(guān)藥物。預(yù)測鈉-葡萄糖協(xié)同轉(zhuǎn)運蛋白2（SGLT2）抑制劑將成為未來抗2型糖尿病藥物的研發(fā)熱點，為抗2型糖尿病的藥物研究指明了新的方向。

Diabetes is a chronic metabolic diseases, and the clinical manifestation is mainly hyperglycemia and microvascular complications. 90%—95% of diabetic patients are type 2 diabetes. The research emphases of type 2 diabetes drug is shifting from the research aim at traditional pathogenic mechanism transferred to the research focus on new target and new pathogenic mechanism in recent years. This paper based on the relevant literature, in accordance with the mechanism of type 2 diabetes, presented a number of drugs in the clinical use or under development. In these drugs, the SGLT2 inhibitors will be the hot topic of the future anti-diabetic drugs, which is indicated a new direction for the research of anti-diabetic drugs.